

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Risk Factors for Contrast-Induced Nephropathy: Protocol for Systematic Review and Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030048
Article Type:	Protocol
Date Submitted by the Author:	27-Feb-2019
Complete List of Authors:	<p>Liu, Yong; Guangdong Cardiovascular Institute Liang, Xingcheng; Guangdong Cardiovascular Institute; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China Xin, Shaojun; Guangdong General Hospital; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China Liu, Jin; Guangdong General Hospital, Sun, Guo-li; Guangdong Cardiovascular Institute, cardiology Chen, Shi-qun; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology cen, xiaolin; Guangdong Cardiovascular Institute; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China dai, xiaohua; Guangdong Cardiovascular Institute; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China He, Yibo; Guangdong Cardiovascular Institute, Song, Feier; Department of Cardiology, Provincial Key Laboratory of Coronary Heart Disease, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510100, China, Cardiology Liang, Yan; Department of Cardiology, Maoming People's Hospital, Maoming, Guangdong, 525000 China Hu, Yu-Ying; Department of Cardiology, First People's Hospital of Kashgar, Kashgar, Xinjiang 844099, China Sciences, Guangzhou, Guangdong, China Zhou, Yingling; Guangdong Cardiovascular Institute chen, zhujun; Guangdong Cardiovascular Institute Tan, Ning; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology Chen, Ji-yan; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology</p>
Keywords:	Coronary angiography, risk factor, contrast-induced nephropathy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

Important Risk Factors for Contrast-Induced Nephropathy: Protocol for Systematic Review and Meta-analysis

Yong Liu^{1§*}, Xingchen Liang^{1,2§}, Shaojun Xing^{1,2§}, Jin Liu^{1§}, Guoli Sun^{1§}, Shiqun Chen^{1§}, Xiaolin Cen^{1,2§}, Xiaohua Dai^{1,2§}, Yibo He¹, Feier Song¹, Yan, Liang³, Yuying Hu⁴, Yingling Zhou^{1,5}, Zhujun Chen¹, Ning Tan¹, Jiyan Chen^{1*}

¹Department of Cardiology, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510000, China

²Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, China

³Department of Cardiology, Maoming People's Hospital, Maoming, Guangdong, 525000 China

⁴Department of Cardiology, First People's Hospital of Kashgar, Kashgar, Xinjiang 844099, China

⁵Guangdong General Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital, Zhuhai), Guangdong, 519040, China

Corresponding Author:

Yong Liu, PhD, MD^a, and Ning Tan PhD, MD^a, Jiyan Chen, PhD, MD^a, FACC, FESC,

^aDepartment of Cardiology, Guangdong provincial Key Laboratory of Coronary Heart Disease

1
2
3
4 Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy
5
6 of Medical Sciences, Guangzhou, Guangdong, 510000, China;
7
8

9
10 E-mail: liuyong2099@126.com (YL), chenjiyandr@126.com (JYC) and tanning100@126.com (NT)
11
12
13
14
15
16
17

18 **Abstract**

19
20 **Introduction:** Identifying the patients who are at risk for contrast-induced
21
22 nephropathy (CIN) is a valuable component for the targeted prevention strategies. The
23
24 absolute and relative importance of risk factors over another has not been
25
26 systematically evaluated, let alone new, controversial or modifiable risk factors of
27
28 CIN.
29

30
31
32
33 **Methods and analysis:** According to MEDLINE, Embase, and Cochrane Central
34
35 databases of Systematic Reviews, we performed systematic review and meta analysis
36
37 to assess the important risk factors, including modifiable, new and controversial ones
38
39 for developing CIN, defined as an increase in serum creatinine after exposure to
40
41 contrast media. The secondary endpoint is all-cause mortality. Two authors will then
42
43 independently screen studies that meet the criteria for inclusion, consulting with a
44
45 third author to resolve any dispute. The quality of the included studies will be
46
47 assessed according to the Newcastle-Ottawa scale.
48
49

50
51 **Ethics and dissemination:** Ethics approval in this systematic review and
52
53 meta-analysis protocol is not needed. We will disseminate the findings of this
54
55 systematic review and meta-analysis via publications in peer-reviewed journals.
56

57 PROSPERO register number: CRD42019121534
58
59
60

1
2
3
4
5
6 **Abbreviations:** CIN=contrast induced nephropathy; GRADE=Grades of
7 Recommendation, Assessment, Development and Evaluation; MACE=major adverse
8 cardiovascular events; STEMI=ST-segment elevation myocardial infarction.
9

10
11
12
13 **Keywords:** Coronary angiography; risk factor; contrast-induced nephropathy.
14
15
16
17

18 **Strengths and limitations of this study**

19
20
21 This will be the first and largest comprehensive, systematic review of diverse risk
22 factors associated with contrast-induced nephropathy (CIN).
23
24

25
26 The broad search strategy will identify clearly identify important risk factors of CIN
27 to preferentially supply target prevention strategies, infrequently reported risk factors
28 and identify new strategies to predict risk of CIN.
29
30

31
32
33 This study will also systematic evaluate modifiable, new and controversial factors,
34 which may be the potential preventive target in the future.
35
36

37
38 This study will only identify English-language articles from the peer-reviewed
39 literature.
40
41
42
43
44

45 **Introduction**

46
47 Contrast-induced nephropathy (CIN) has been reported to be associated with poor
48 clinical outcomes including an increased short and long-term mortality, prolonging
49 the duration of hospital stays, the need for renal replacement therapy, and an increase
50 in major adverse cardiac events^{1,2}. Critical predisposing factors for CIN include older
51 age, preexisting renal failure, hemodynamic instability, congestive heart failure,
52 diabetes mellitus, anemia, and the volume of contrast media^{3,4}. Allen and Silve et al.^{5,6}
53 did systematically evaluation for current predict models for CIN, but there has been
54
55
56
57
58
59
60

1
2
3
4 no systematic assessment absolute and relative importance of risk factors over
5 another, let alone new, controversial risk factors of CIN.
6
7

8 To address this deficit in knowledge, we conducted a systematic review and a
9 meta-analysis of the observational studies that examined the absolute and relative
10 importance of risk factors of CIN.
11
12
13
14
15
16

17 **Objectives**

18 The objective of this study is to identify the relationship between multiple risk factors
19 and CIN. More specifically, the goals of this study are the following:
20
21
22

- 23 1. To comprehensively and systematically assess the absolute and relative importance
24 of current common risk factors for CIN;
25
26
- 27 2. To systematically assess the new, controversial risk factors for CIN.
28
29
30
31

32 **Method**

33 ***Patient and public involvement***

34 This is a protocol for meta analysis and it was not appropriate or possible to involve
35 patients or the public in this work.
36
37

38 ***Search strategy***

39 A systematic computer-aided search of related studies was conducted in the following
40 manner:
41
42

- 43 1. Ovid MEDLINE;
- 44 2. Ovid Embase;
- 45 3. Cochrane Database of Systematic Reviews.>

46 ***Initial keywords***

47 The databases will be searched using the following initial keyword search terms:
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 coronary angiography; angiocardiograph; contrast medium; radiocontrast medium;
5 acute kidney injury ; contrast-induced nephropathy ; risk factor ; risk Assessment.
6
7 We will search the databases we choose from the present with restrictions on the
8 English language of publication. If we find additional relevant keywords during any
9 of the electronic searches or others, we will modify the electronic search strategies to
10 upgrade these terms and document the changes.
11
12
13
14
15
16
17

18 **Types of studies**

19
20 We will include all observational studies (registries, cohorts, etc.) analyzing the
21 correlation between risk factors and CIN following procedures with contrast media.
22 This review will also consider experimental and epidemiological study designs,
23 including case-control and cohort studies as being appropriate for inclusion in the
24 meta-analysis. However, we will exclude articles related to animal experiments.
25
26
27
28
29
30
31
32
33

34 **Types of participants**

35 We will include adults aged 18 years and above, identified with the CIN.
36
37
38
39
40
41
42

43 **Types of outcomes**

44 *Primary outcome*

45
46 The primary endpoint is CIN, defined as an increase in serum creatinine after
47 exposure to contrast media.
48
49
50
51
52

53 *Secondary outcome*

54
55 Long-term all-cause mortality is defined as death from any cause within the follow-up
56 time of patient's post-index procedure.
57
58
59
60

Selection of studies

We will filter all retrieved articles. Two authors (XCL and SJX) will browse the title and abstract independently, and the two authors will record the exclude documents and the reasons for the exclusion. If there is a dispute in the process of the screening of the article, there will be a third author (LY) to arbitrate. After the initial screening, the two authors will then read the full text and further filter the articles according to the inclusion and exclusion criteria mentioned above. The same queue of the population will be treated as the same study and then excluded. In the process of reading the full text, if there is doubt in the selection, the two authors (XCL and SJX) will discuss it. If it cannot be resolved, there will be a third author (LY) to arbitrate. Finally, all selected articles will be listed for further analysis, and the excluded articles will be classified according to the reasons for exclusion.

Quality assessment/assessment of the risk of bias in included studies

Two authors will independently assess the quality of selected articles using the *Newcastle-Ottawa Scale*⁷.

Observational studies using Newcastle-Ottawa Scale:

CASE-CONTROL STUDIES

Selection

- 1) Is the Case Definition Adequate?
- 2) Representativeness of the Cases
- 3) Selection of Controls
- 4) Definition of Controls

1
2
3 Comparability
4

- 5
6 1) Comparability of Cases and Controls on the Basis of the Design or Analysis
7

8 Exposure
9

- 10 1) Ascertainment of Exposure
11

- 12 2) Non-Response Rate
13

14 COHORT STUDIES
15

16 Selection
17

- 18 1) Representativeness of the Exposed Cohort
19

- 20 2) Selection of the Non-Exposed Cohort
21

- 22 3) Ascertainment of Exposure
23

- 24 4) Demonstration That Outcome of Interest Was Not Present at Start of Study
25
26
27

28 Comparability
29

- 30 1) Comparability of Cohorts on the Basis of the Design or Analysis
31
32

33 Outcome
34

- 35 1) Assessment of Outcome
36

- 37 2) Was Follow-Up Long Enough for Outcomes to Occur
38

- 39 3) Adequacy of Follow Up of Cohorts
40
41
42
43
44
45

46 We will rate each selected article with a rating of low, high or unclear and the results
47 will be presented in the form of a table. Unpublished data will be considered in the
48 evaluation of the publication bias, and we will try to contact the author for assistance
49 in this regard.
50
51
52
53
54
55

56
57 **Data synthesis:**
58

59 We will use STATA Ver13.0 software and RevMan for data analysis, and risk factor
60

1
2
3
4 effect sizes will be expressed as an odds ratio and their 95% CI. Using standard
5
6 chi-square test to assess the heterogeneity and variable statistics, we will perform
7
8 subgroup analysis to conduct data statistics. If there is data that cannot be counted in
9
10 the selected article, the data will be listed in the form of a table or chart. EndNote will
11
12 be used for managing references.

13
14 Sensitivity analysis. We will perform sensitivity analyses in order to explore the
15
16 influence of the following factors on effect sizes.

- 17
18 1. Restricting the analysis to studies for coronary angiography.
- 19
20 2. Restricting the analysis to large cohort studies with more than 1000 subjects.

21 22 23 24 **Conclusion:**

25
26
27 The goal of this systematic review and meta-analysis is to clearly identify important
28
29 risk factors of CIN to preferentially supply target prevention strategies, including
30
31 contrast limiting and hydration, for those high risk factors^{8,9,10}. In addition modifiable,
32
33 new and controversial factors may be the potential preventive target in the future.

34 35 36 37 38 **Author affiliations**

39 40 41 **Contributions**

42
43
44 Yong Liu, Xingchen Liang, Shaojun Xing, Jin Liu, Guoli Sun, Shiqun Chen, Xiaolin
45
46 Cen, Xiaohua Dai, Yibo He, Feier Song, Yan Liang, Yuying Hu, Yingling Zhou,
47
48 Zhujun Chen, Ning Tan, Jiyan Chen: conception and design of the work; Yong Liu,
49
50 Xingchen Liang, Shaojun Xing, Xiaolin Cen, Xiaohua Dai: determining search terms,
51
52 related literature search; Yong Liu, Xingchen Liang, Shaojun Xing, Jin Liu, Guoli
53
54 Sun, Shiqun Chen, Xiaolin Cen, Xiaohua Dai, Yibo He, Feier Song: filter literature
55
56 according to established standards; Yan Liang, Yuying Hu, Yingling Zhou, Zhujun
57
58 Chen, Ning Tan, Jiyan Chen: as a third author, judge the doubtful literature; Yong
59
60 Liu, Shiqun Chen: acquisition, analysis, or interpretation of data; Yong Liu, Shiqun Chen,

1
2
3
4 Jiyang Chen, Yong Liu, Ning Tan: drafting the work or revising it critically for important
5 intellectual content. All authors agree that this is the final version of the article. All authors agreed
6 to be accountable for all aspects of the work in ensuring that questions related to the accuracy or
7 integrity of any part of the work are appropriately investigated and resolved.
8
9
10

11 ***Competing interests***

12
13
14
15 The authors declare no competing interests.
16

17 ***Funding***

18
19
20 The study is supported by the Science and Technology Planning Project of
21 Guangdong Province (grant no. 2014B070706010), The Technology Planning Project
22 of Dongguan Province (grant no. 2015108101022), The National Science Foundation
23 for Young Scientists of China (grant no. 81500520) and The Progress in Science and
24 Technology Project of Guangdong Province (grant no. 2015A030302037) .
25
26
27
28
29

30 ***Data sharing statement***

31
32 All authors will share all data.
33
34
35
36
37
38
39

40 **References**

- 41
42 1. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, Kosiborod
43 M, Amin AP, Messenger JC, Rumsfeld JS, Spertus JA. Contemporary incidence,
44 predictors, and outcomes of acute kidney injury in patients undergoing percutaneous
45 coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc*
46 *Interv.* 2014 Jan;7(1):1-9.
47
48
49
50
51
52 2. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson
53 ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of
54 adverse clinical outcomes after coronary angiography: a systematic review and
55 meta-analysis. *Circ Cardiovasc Interv.* 2013 Feb;6(1):37-43.
56
57
58
59
60

- 1
2
3
4 3. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of
5 contrast-induced nephropathy after percutaneous coronary intervention: development
6 and initial validation. *J Am Coll Cardiol*. 2004;44:1393–1399.
7
8
- 9
10 4. Gurm HS, Seth M, Kooiman J, Share D. A novel tool for reliable and accurate
11 prediction of renal complications in patients undergoing percutaneous coronary
12 intervention. *J Am Coll Cardiol*. 2013 Jun 4;61(22):2242-8.
13
14
- 15 5. Allen DW, Ma B, Leung KC, Graham MM, Pannu N, Traboulsi M, Goodhart D,
16 Knudtson ML, James MT. Risk Prediction Models for Contrast-Induced Acute
17 Kidney Injury Accompanying Cardiac Catheterization: Systematic Review and
18 Meta-analysis. *Can J Cardiol*. 2017 Jun;33(6):724-736.
19
20
- 21 6. Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction
22 models for contrast induced nephropathy: systematic review. *BMJ*. 2015 Aug
23 27;351:h4395. doi: 10.1136/bmj.h4395.
24
25
- 26 7. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
27 Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in
28 meta-analyses [webpage on the Internet] Ottawa, ON: Ottawa Hospital Research
29 Institute; 2011. [Accessed February 5, 2013]. Available
30 from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
31
32
- 33 8. Liu Y, Chen JY, Tan N, Liu Y, Chen JY, Tan N, Zhou YL, Yu DQ, Chen ZJ, He
34 YT, Liu YH, Luo JF, Huang WH, Li G, He PC, Yang JQ, Xie NJ, Liu XQ, Yang DH,
35 Huang SJ, Piao-Ye, Li HL, Ran P, Duan CY, Chen PY. Safelimits of contrast vary
36 with hydration volume for prevention of contrast-induced nephropathy after coronary
37 angiography among patients with a relatively low risk of contrast-induced
38 nephropathy. *Circ Cardiovasc Interv* 2015;8.pii: e001859.
39
40
- 41 9. Briguori C, Signoriello G. Acute kidney injury: Intravenous hydration for the
42 prevention of CIAKI. *Nat Rev Nephrol*. 2017 May;13(5):264-266.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 10. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, Dua A,
5 Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of
6 contrast-induced acute kidney injury: the POSEIDON randomised controlled trial.
7
8 Lancet. 2014 May 24;383(9931):1814-23.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Risk factors for contrast-induced acute kidney injury (CI-AKI): Protocol for systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030048.R1
Article Type:	Protocol
Date Submitted by the Author:	05-Jun-2019
Complete List of Authors:	<p>Liu, Yong; Guangdong Cardiovascular Institute Liang, Xingcheng; Guangdong Cardiovascular Institute; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China Xin, Shaojun; Guangdong General Hospital; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China Liu, Jin; Guangdong General Hospital, Sun, Guo-li; Guangdong Cardiovascular Institute, cardiology Chen, Shi-qun; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology cen, xiaolin; Guangdong Cardiovascular Institute; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China dai, xiaohua; Guangdong Cardiovascular Institute; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China He, Yibo; Guangdong Cardiovascular Institute, Song, Feier; Department of Cardiology, Provincial Key Laboratory of Coronary Heart Disease, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510100, China, Cardiology Liang, Yan; Department of Cardiology, Maoming People's Hospital, Maoming, Guangdong, 525000 China Hu, Yu-Ying; Department of Cardiology, First People's Hospital of Kashgar, Kashgar, Xinjiang 844099, China Sciences, Guangzhou, Guangdong, China Zhou, Yingling; Guangdong Cardiovascular Institute chen, zhujun; Guangdong Cardiovascular Institute Tan, Ning; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology Chen, Ji-yan; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology</p>
Primary Subject Heading:	Cardiovascular medicine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Coronary angiography, risk factor, contrast-induced nephropathy



1
2
3
4
5 **Risk factors for contrast-induced acute kidney injury (CI-AKI):**
6
7
8 **Protocol for systematic review and meta-analysis**
9

10
11
12
13 Yong Liu^{1§}, Xingchen Liang^{1,2§}, Shaojun Xin^{1,2§}, Jin Liu^{1§}, Guoli Sun^{1§}, Shiqun
14
15 Chen^{1§}, Xiaolin Cen^{1,2§}, Xiaohua Dai^{1,2§}, Yibo He¹, Feier Song¹, Yan, Liang³, Yuying
16
17 Hu⁴, Yingling Zhou^{1,5}, Zhujun Chen¹, Ning Tan^{1*}, Jiyan Chen^{1*}
18
19

20
21 ¹Department of Cardiology, Guangdong provincial Key Laboratory of Coronary Heart Disease
22
23 Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy
24
25 of Medical Sciences, Guangzhou, Guangdong, 510000, China
26
27

28
29 ²Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, China
30

31
32 ³Department of Cardiology, Maoming People's Hospital, Maoming, Guangdong, 525000 China
33

34
35 ⁴Department of Cardiology, First People's Hospital of Kashgar, Kashgar, Xinjiang 844099, China
36

37
38 ⁵Guangdong General Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital, Zhuhai),
39
40 Guangdong, 519040, China
41

42
43
44 Corresponding Authors:
45

46
47 Jiyan Chen, PhD, MD^a, FACC, FESC and Ning Tan PhD, MD^a
48

49
50 Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease
51
52 Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy
53
54 of Medical Sciences, Guangzhou, Guangdong, 510000, China;
55

56
57 E-mail: chenjiyandr@126.com (JYC), and tanning100@126.com (NT)
58
59
60

Abstract

Introduction: Identifying the patients who are at risk for contrast-induced acute kidney injury (CI-AKI), which is defined as an increase in serum creatinine after exposure to contrast media, is a critical step in targeted prevention strategies. The absolute and relative importance of individual risk factors have not been systematically evaluated, let alone the new, controversial, and modifiable risk factors of CI-AKI.

Methods and analysis: On December 17th, 2018, a search was performed on MEDLINE, Embase, and the Cochrane Database of Systematic Reviews. We will perform a systematic review and meta-analysis to assess the important risk factors for developing CI-AKI, including those new, modifiable factors which are considered controversial. The secondary endpoint will be all-cause mortality. Two authors will then independently screen studies that meet the criteria for inclusion, consulting with a third author to resolve any dispute. The quality of the included studies will be assessed according to the Newcastle-Ottawa scale.

Ethics and dissemination: Ethics approval in this systematic review and meta-analysis protocol is not needed. We will disseminate the findings of this systematic review and meta-analysis via publications in peer-reviewed journals.

PROSPERO register number: CRD42019121534

Abbreviations: CI-AKI = contrast-induced acute kidney injury; GRADE = Grades of Recommendation, Assessment, Development and Evaluation; MACE = major adverse cardiovascular events; STEMI = ST-segment elevation myocardial infarction.

Keywords: Coronary angiography; risk factor; contrast-induced nephropathy.

Strengths and limitations of this study

This will be the first, and largest, comprehensive systematic review of the diverse risk factors associated with CI-AKI.

Our broad search strategy will identify the important risk factors for CI-AKI for the purpose of preferentially supplying target prevention strategies, bringing attention to infrequently reported risk factors, and identifying new strategies to predict the risk of CI-AKI.

This study will also evaluate the new, modifiable risk factors, which are still considered controversial but may hold promise as preventive targets in the future.

This study will only select English-language articles from the peer-reviewed literature.

Introduction

Contrast-induced acute kidney injury (CI-AKI) has been reported to be associated with poor clinical outcomes including increased short and long-term mortality, prolonged duration of hospital stay, the need for renal replacement therapy, and an increase in major adverse cardiac events^{1,2}. The use of a risk prediction tool for CI-AKI could have several benefits. Primarily, it may help identify those patients at high risk for the disorder who might benefit from perioperative strategies that protect the kidneys. Critical predisposing factors for CI-AKI include older age, preexisting renal failure, hemodynamic instability, congestive heart failure, diabetes mellitus, anemia, and the volume of contrast media^{3,4}. Although Allen et al.⁵ and Silver et al.⁶ systematically evaluated the current predictive models for CI-AKI, there has been no systematic assessment of the absolute and relative importance of the individual risk factors for CI-AKI, let alone, the new, modifiable, and controversial ones. This will be the first, and largest systematic review about the risk factors associated with CI-AKI.

To address this deficit in knowledge, we will conduct a systematic review and a meta-analysis of the observational studies that have examined the absolute and relative importance of the risk factors of CI-AKI.

Objectives

The objective of this study is to identify the relationship between the multiple risk factors of CI-AKI. More specifically, the goals of this study are the following:

1. To comprehensively and systematically assess the absolute and relative importance of the current common risk factors for CI-AKI
2. To systematically assess the new, controversial risk factors for CI-AKI

Method

Patient and public involvement

This is a protocol for a meta-analysis, and it will be not appropriate or possible to involve patients or the public in this work.

Search strategy

A systematic computer-aided search of related studies will be conducted in the following databases:

1. Ovid MEDLINE
2. Ovid Embase
3. Cochrane Database of Systematic Reviews

Initial keywords

The databases will be searched using the following initial keyword search terms: coronary angiography; angiocardiograph; contrast medium; radiocontrast medium; acute kidney injury; contrast-induced nephropathy; acute renal insufficiency; risk factor; risk assessment; multivariate analysis; multivariable logistic regression; models. We will restrict the search on the databases to English language publications. If we find additional relevant keywords during any of the electronic searches, we will update the electronic search strategies with these terms and document the changes (details in Supplement).

Types of studies

We will include all observational studies (registries, cohorts, etc.) that analyze the correlation between risk factors and CI-AKI following procedures with contrast media. This review will also consider experimental and epidemiological study designs, including case-control and cohort studies, as being appropriate for inclusion in the meta-analysis. However, we will exclude articles related to animal experiments.

Types of participants

We will include adults identified with the CI-AKI who are aged 18 years and above.

Types of outcomes

Primary outcome

The primary endpoint will be CI-AKI, defined as an increase in serum creatinine after exposure to contrast media.

Secondary outcome

The secondary endpoint will be long-term all-cause mortality, defined as death from any cause within the follow-up time of patient's post-index procedure.

Selection of studies

We will filter all retrieved articles. Two authors (XCL and SJX) will browse the titles and abstracts independently, and will record the excluded documents and the reasons for the exclusion. If there is a dispute in the process of the screening of the article, there will be a third author (YL) to arbitrate. After the initial screening, the two authors (GLS and JY) will then read the full text and further filter the articles according to the inclusion and exclusion criteria mentioned above. To avoid overlapping patient data in duplicate publications, registry analyses will be cross-checked with institutional studies and compared with other registry studies, and the larger or more complete publication will be included. In the process of reading the full text, if there is doubt in the selection, the two authors (XCL and SJX) will discuss it. If it cannot be resolved, there will be a third author (LY) to arbitrate. Finally, all selected articles will be listed for further analysis, and the excluded articles will be classified according to the reasons for exclusion.

Quality assessment/assessment of the risk of bias in included studies

Two authors will independently assess the quality of selected articles using the *Newcastle-Ottawa Scale*⁷.

Observational studies using Newcastle-Ottawa Scale:

CASE-CONTROL STUDIES

Selection

- 1) Is the Case Definition Adequate?
- 2) Representativeness of the Cases
- 3) Selection of Controls
- 4) Definition of Controls

Comparability

- 1) Comparability of Cases and Controls on the Basis of the Design or Analysis

Exposure

- 1) Ascertainment of Exposure

1
2
3 2) Non-Response Rate

4 COHORT STUDIES

5 Selection

6
7 1) Representativeness of the Exposed Cohort

8 2) Selection of the Non-Exposed Cohort

9 3) Ascertainment of Exposure

10 4) Demonstration That Outcome of Interest Was Not Present at Start of Study

11 Comparability

12 1) Comparability of Cohorts on the Basis of the Design or Analysis

13 Outcome

14 1) Assessment of Outcome

15 2) Was Follow-Up Long Enough for Outcomes to Occur

16 3) Adequacy of Follow-Up of Cohorts

17 We will rate each selected article with a rating of low, high, or unclear, and the results
18 will be presented in the form of a table. Unpublished data will be considered in the
19 evaluation of the publication bias, and we will try to contact the author for assistance
20 in this regard. In addition, we will use the Risk of Bias in Nonrandomized studies of
21 Interventions tool (ROBINS-I)⁸ to enhance the reproducibility and comparability of
22 this review to future reviews of a similar topic.
23
24
25
26
27
28
29
30
31

32 **Data synthesis:**

33 We will use STATA Ver13.0 software and RevMan for data analysis, and risk factor
34 effect sizes will be expressed as an odds ratio and their 95% CI. Using standard
35 chi-square test to assess the heterogeneity and variable statistics, we will perform
36 subgroup analysis to conduct data statistics. If there are data that cannot be counted in
37 the selected article, the data will be listed in the form of a table or chart. EndNote will
38 be used for managing references.
39

40 Sensitivity analysis. We will perform sensitivity analyses in order to explore the
41 influence of the following factors on effect sizes:
42

43 1. Restricting the analysis to studies of coronary angiography.

44 2. Restricting the analysis to large cohort studies with more than 1000 subjects.
45
46
47
48
49
50
51
52
53
54

55 **Conclusion:**

56 The goal of this systematic review and meta-analysis is to clearly identify the
57 important risk factors for CI-AKI for the purpose of preferentially supplying target
58
59
60

1
2
3
4 prevention strategies, including contrast limiting and hydration for those high risk
5 factors⁹⁻¹¹. In addition, the modifiable, new, and controversial factors will also be
6 evaluated, as they may have potential as preventive targets.
7
8
9
10
11
12
13
14

15 **Author affiliations**

16 ***Contributions***

17
18 Yong Liu, Xingchen Liang, Shaojun Xin, Jin Liu, Guoli Sun, Shiqun Chen, Xiaolin
19 Cen, Xiaohua Dai, Yibo He, Feier Song, Yan Liang, Yuying Hu, Yingling Zhou,
20 Zhujun Chen, Ning Tan, Jiyan Chen: conception and design of the work; Yong Liu,
21 Xingchen Liang, Shaojun Xin, Xiaolin Cen, Xiaohua Dai: determining search terms,
22 related literature search; Yong Liu, Xingchen Liang, Shaojun Xin, Jin Liu, Guoli Sun,
23 Shiqun Chen, Xiaolin Cen, Xiaohua Dai, Yibo He, Feier Song: filter literature
24 according to established standards; Yan Liang, Yuying Hu, Yingling Zhou, Zhujun
25 Chen, Ning Tan, Jiyan Chen: as a third author, judge the doubtful literature; Yong Liu,
26 Shiqun Chen, Xiaolin Cen, Xiaohua Dai, Yibo He, Feier Song: acquisition, analysis, or interpretation of data; Yong Liu, Shiqun Chen,
27 Jiyan Chen, Yong Liu, Ning Tan: drafting the work or revising it critically for
28 important intellectual content. All authors agree that this is the final version of the
29 article. All authors agree to be accountable for all aspects of the work in ensuring that
30 questions related to the accuracy or integrity of any part of the work are appropriately
31 investigated and resolved.
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 ***Competing interests***

47
48 None declared
49

50 ***Funding***

51
52 The study is supported by the Science and Technology Planning Project of
53 Guangdong Province (grant no. 2014B070706010), The Technology Planning Project
54 of Dongguan Province (grant no. 2015108101022), The National Science Foundation
55 for Young Scientists of China (grant no. 81500520), and The Progress in Science and
56 Technology Project of Guangdong Province (grant no. 2015A030302037) .
57
58
59
60

Data sharing statement

All authors will share all data.

References

1. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, Kosiborod M, Amin AP, Messenger JC, Rumsfeld JS, Spertus JA. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc Interv.* 2014 Jan;7(1):1-9.
2. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. *Circ Cardiovasc Interv.* 2013 Feb;6(1):37-43.
3. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol.* 2004;44:1393–1399.
4. Gurm HS, Seth M, Kooiman J, Share D. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol.* 2013 Jun 4;61(22):2242-8.
5. Allen DW, Ma B, Leung KC, Graham MM, Pannu N, Traboulsi M, Goodhart D, Knudtson ML, James MT. Risk Prediction Models for Contrast-Induced Acute Kidney Injury Accompanying Cardiac Catheterization: Systematic Review and Meta-analysis. *Can J Cardiol.* 2017 Jun;33(6):724-736.
6. Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. *BMJ.* 2015 Aug 27;351:h4395. doi: 10.1136/bmj.h4395.

- 1
2
3
4 7. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
5 Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in
6 meta-analyses [webpage on the Internet] Ottawa, ON: Ottawa Hospital Research
7 Institute; 2011. [Accessed February 5, 2013]. Available
8 from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
9
10
- 11 8. Sterne Ac, Hernán M A, Reeves B C, et al. ROBINS-I: a tool for assessing risk of
12 bias in non-randomised studies of interventions. *BMJ*, 2016, 355: i4919.
13
- 14 9. Liu Y, Chen JY, Tan N, Liu Y, Chen JY, Tan N, Zhou YL, Yu DQ, Chen ZJ, He
15 YT, Liu YH, Luo JF, Huang WH, Li G, He PC, Yang JQ, Xie NJ, Liu XQ, Yang DH,
16 Huang SJ, Piao-Ye, Li HL, Ran P, Duan CY, Chen PY. Safelimits of contrast vary
17 with hydration volume for prevention of contrast-induced nephropathy after coronary
18 angiography among patients with a relatively low risk of contrast-induced
19 nephropathy. *Circ Cardiovasc Interv* 2015;8.pii: e001859.
20
21
- 22 10. Briguori C, Signoriello G. Acute kidney injury: Intravenous hydration for the
23 prevention of CIAKI. *Nat Rev Nephrol*. 2017 May;13(5):264-266.
24
25
- 26 11. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, Dua A,
27 Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of
28 contrast-induced acute kidney injury: the POSEIDON randomised controlled trial.
29 *Lancet*. 2014 May 24;383(9931):1814-23.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Draft MEDLINE and EMBASE search - Ovid interface

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- 1. exp Contrast Media/
 - 2. (contrast media or contrast medium or contrast material\$ or contrast agent\$ or contrast dye or radiographic contrast).ti,ab.
 - 3. (radiocontrast media or radiocontrast medium or radiocontrast agent\$).ti,ab.
 - 4. 1 or 2 or 3
 - 5. (nephritis or nephropath\$ or nephrotoxic\$).ti,ab.
 - 6. ((impair\$ or damag\$ or reduc\$ or injur\$ dysfunction\$ or failure) adj2 (renal or kidney)).ti,ab.
 - 7. exp Kidney Diseases/
 - 8. exp nephritis/ or diabetic nephropathies/
 - 9. exp renal insufficiency/
 - 10. acute kidney injury.ti,ab.
 - 11. acute kidney injur*.ti,ab.
 - 12. acute kidney failure*.ti,ab.
 - 13. Acute kidney insufficienc*.ti,ab.
 - 14. contrast induced nephropathy
 - 15. contrast induced nephropath*.ti,ab.
 - 16. contrast nephropath*.ti,ab.
 - 17. contrast induced acute kidney injur*.ti,ab.
 - 18. AKI.ti,ab.
 - 19. ARF.ti,ab.
 - 20. CIN.ti,ab.
 - 21. acute renal injur*.ti,ab.
 - 22. acute renal failure*.ti,ab.
 - 23. acute renal insufficienc*.ti,ab.
 - 24. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
 - 25. Risk Assessment/
 - 26. risk factors/

- 1
2
3
4 -27. (risk adj3 model*).ti,ab.
5
6 -28. score*.ti,ab.
7
8 -29. Forecasting/
9
10 -30. prognostic factor*.ti,ab.
11
12 -31. "Predictive Value of Tests"/
13
14 -32. predict*.ti,ab.
15
16 -33. regression*.ti,ab.
17
18 -34. (logistic adj2 model*).ti,ab.
19
20 -35. multivariate analysis/
21
22 -36. multivariable logistic regression
23
24 -37. (multivariate adj3 analysis).ti,ab.
25
26 -38. sn.fs.
27
28 -39. exp mathematical concepts/
29
30 -40. exp Models, Biological/
31
32 -41. exp models, statistical/
33
34 -42. area under curve/
35
36 -43. algorithm*.ti,ab.
37
38 -44. equation*.ti,ab.
39
40 -45. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or
41
42 39 or 40 or 41 or 42 or 43 or 44
43
44 -46. 4 and 24 and 45
45
46 -47. remove duplicates from 46
47
48
49 Draft Cochrane datebase search
50
51 -1. (contrast media or contrast medium or contrast material\$ or contrast agent\$ or
52
53 contrast dye or radiographic contrast).ti,ab.
54
55 -2. (radiocontrast media or radiocontrast medium or radiocontrast agent\$).ti,ab.
56
57 -3. (percutaneous coronary intervention or PCI or coronary angiograph or
58
59 angiography or catheter-proven or Angioplasty).ti,ab.
60
60 -4. 1 or 2 or 3

1
2
3
4 -5. (nephritis or nephropath\$ or nephrotoxic\$).ti,ab.

5
6 -6. ((impair\$ or damag\$ or reduc\$ or injur\$ dysfunction\$ or failure) adj2 (renal or
7 kidney)).ti,ab.

8
9
10 -7. (Kidney Diseases or nephritis or diabetic nephropathies or renal insufficiency or
11 acute kidney injury or acute kidney injur* or acute kidney failure* or Acute kidney
12 insufficienc* or contrast induced nephropathy or contrast induced nephropath* or
13 contrast nephropath* or contrast induced acute kidney injur* or AKI or ARF or CIN
14 or acute renal injur* or acute renal failure* or acute renal insufficienc* or creatinine
15 or serum creatinine).ti,ab.

16
17
18
19
20
21 -8. 5 or 6 or 7

22
23 -9. ((risk adj3 model*) or score* or prognostic factor* or predict* or regression* or
24 (logistic adj2 model*) or multivariable logistic regression or multivariable analyses or
25 logistic regression or algorithm* or equation* or (multivariate adj3 analysis or
26 Forecasting or "Predictive Value of Tests" or multivariate analysis or mathematical
27 concepts or Models, Biological or models, statistical or area under curve)).ti,ab.

28
29
30
31
32
33 -10. 4 and 8 and 9
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a-P1	Identify the report as a protocol of a systematic review
Update	NO	If the protocol is for an update of a previous systematic review, identify as such
Registration	2-P2	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		
Contact	3a-P1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	3b-P1	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	NO	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a-P8	Indicate sources of financial or other support for the review
Sponsor	5b-P8	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c-P8	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	6-P3	Describe the rationale for the review in the context of what is already known
Objectives	7-P3	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		
Eligibility criteria	8-P6	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9-P4	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	10-P4	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:		
Data management	11a-P7	Describe the mechanism(s) that will be used to manage records and data throughout the review

1			
2			
3	Selection process	11b-P6	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
4			
5	Data collection process	11c-P6	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
6			
7	Data items	12-P6	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
8			
9	Outcomes and prioritization	13-P5	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
10			
11	Risk of bias in individual studies	14-P7	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
12			
13	Data synthesis	15a-P7	Describe criteria under which study data will be quantitatively synthesised
14		15b-P7	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
15		15c-P7	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
16		15d-P7	If quantitative synthesis is not appropriate, describe the type of summary planned
17			
18	Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
19			
20	Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)
21			

22 *** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important**
 23 **clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the**
 24 **PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

25
 26 *From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and*
 27 *meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

BMJ Open

Risk factors for contrast-induced acute kidney injury (CI-AKI): Protocol for systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030048.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Jul-2019
Complete List of Authors:	Liu, Yong; Guangdong Provincial People's Hospital Liang, Xingcheng; Guangdong Provincial People's Hospital; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China Xin, Shaojun; Guangdong Provincial People's Hospital; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China Liu, Jin; Guangdong Provincial People's Hospital Sun, Guo-li; Guangdong Provincial People's Hospital Chen, Shi-qun; Guangdong Provincial People's Hospital cen, xiaolin; Guangdong Provincial People's Hospital; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China dai, xiaohua; Guangdong Provincial People's Hospital; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China He, Yibo; Guangdong Provincial People's Hospital Song, Feier; Guangdong Provincial People's Hospital Liang, Yan; Maoming People's Hospital, Cardiology Hu, Yu-Ying; Department of Cardiology, First People's Hospital of Kashgar, Kashgar, Xinjiang844099, ChinaSciences, Guangzhou, Guangdong, China Zhou, Yingling; Guangdong Provincial People's Hospital chen, zhujun; Guangdong Provincial People's Hospital Tan, Ning; Guangdong Provincial People's Hospital Chen, Ji-yan; Guangdong Provincial People's Hospital
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Coronary angiography, risk factor, contrast-induced nephropathy

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **Risk factors for contrast-induced acute kidney injury (CI-AKI):**
6
7
8 **Protocol for systematic review and meta-analysis**
9
10

11
12
13 Yong Liu^{1§}, Xingchen Liang^{1,2§}, Shaojun Xin^{1,2§}, Jin Liu^{1§}, Guoli Sun^{1§}, Shiqun Chen^{1§},
14
15 Xiaolin Cen^{1,2§}, Xiaohua Dai^{1,2§}, Yibo He¹, Feier Song¹, Yan, Liang³, Yuying Hu⁴,
16
17 Yingling Zhou^{1,5}, Zhujun Chen¹, Ning Tan^{1*}, Jiyan Chen^{1*}
18
19

20
21 ¹Department of Cardiology, Guangdong provincial Key Laboratory of Coronary Heart Disease
22
23 Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of
24
25 Medical Sciences, Guangzhou, Guangdong, 510000, China
26
27

28
29 ²Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, China
30

31
32 ³Department of Cardiology, Maoming People's Hospital, Maoming, Guangdong, 525000 China
33

34
35 ⁴Department of Cardiology, First People's Hospital of Kashgar, Kashgar, Xinjiang 844099, China
36

37
38 ⁵Guangdong General Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital, Zhuhai),
39
40 Guangdong, 519040, China
41

42
43
44 Corresponding Authors:
45

46
47 Jiyan Chen, PhD, MD^a, FACC, FESC and Ning Tan PhD, MD^a
48

49
50 Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease
51
52 Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy
53
54 of Medical Sciences, Guangzhou, Guangdong, 510000, China;
55

56
57 E-mail: chenjiyandr@126.com (JYC), and tanning100@126.com (NT)
58
59
60

Abstract

Introduction: Identifying the patients who are at risk for contrast-induced acute kidney injury (CI-AKI), which is defined as an increase in serum creatinine after exposure to contrast media, is a critical step in targeted prevention strategies. The absolute and relative importance of individual risk factors have not been systematically evaluated, let alone the new, controversial, and modifiable risk factors of CI-AKI.

Methods and analysis: On July 1st, 2019, a search was performed on MEDLINE, Embase, and the Cochrane Database of Systematic Reviews. We will perform a systematic review and meta-analysis to assess the important risk factors for developing CI-AKI, including those new, modifiable factors which are considered controversial. The secondary endpoint will be all-cause mortality. Two authors will then independently screen studies that meet the criteria for inclusion, consulting with a third author to resolve any dispute. The quality of the included studies will be assessed according to the Newcastle-Ottawa scale.

Ethics and dissemination: Ethics approval in this systematic review and meta-analysis protocol is not needed. We will disseminate the findings of this systematic review and meta-analysis via publications in peer-reviewed journals.

PROSPERO register number: CRD42019121534

Abbreviations: CI-AKI = contrast-induced acute kidney injury; GRADE = Grades of Recommendation, Assessment, Development and Evaluation; MACE = major adverse cardiovascular events; STEMI = ST-segment elevation myocardial infarction.

Keywords: Coronary angiography; risk factor; contrast-induced nephropathy.

Strengths and limitations of this study

This will be the first, and largest, comprehensive systematic review of the diverse risk factors associated with CI-AKI.

Our broad search strategy will identify the important risk factors for CI-AKI for the purpose of preferentially supplying target prevention strategies, bringing attention to infrequently reported risk factors, and identifying new strategies to predict the risk of CI-AKI.

This study will also evaluate the new, modifiable risk factors, which are still considered controversial but may hold promise as preventive targets in the future.

This study will only select English-language articles from the peer-reviewed literature.

Introduction

Contrast-induced acute kidney injury (CI-AKI) has been reported to be associated with poor clinical outcomes including increased short and long-term mortality, prolonged duration of hospital stay, the need for renal replacement therapy, and an increase in major adverse cardiac events.^{1 2} The use of a risk prediction tool for CI-AKI could have several benefits. Primarily, it may help identify those patients at high risk for the disorder who might benefit from some prevention strategies like intravenous isotonic saline hydration which has been proven to be effective, statins and acetylcysteine that are controversial, or other interventions targeting the risk factors that will be identified in this meta-analysis in progress.³ Critical predisposing factors for CI-AKI include older age, preexisting renal failure, hemodynamic instability, congestive heart failure, diabetes mellitus, anemia, and the volume of contrast media.^{4 5} Although Allen et al.⁶ and Silver et al.⁷ systematically evaluated the current predictive models for CI-AKI, there has been no systematic assessment of the absolute and relative importance of the individual risk factors for CI-AKI, let alone, the new, modifiable, and controversial one, for example, the usage of ACEI/ARB or diuretics, smoking and body mass index.³ This will be the first, and largest systematic review about the risk factors associated with CI-AKI. To address this deficit in knowledge, we will conduct a systematic review and a meta-analysis of the observational studies that have examined the absolute and relative importance of the risk factors of CI-AKI.

Objectives

The objective of this study is to identify the relationship between the multiple risk factors of CI-AKI. More specifically, the goals of this study are the following:

1. To comprehensively and systematically assess the absolute and relative importance of the current common risk factors for CI-AKI
2. To systematically assess the new, controversial risk factors for CI-AKI

Method

Patient and public involvement

This is a protocol for a meta-analysis, and it will be not appropriate or possible to

1
2
3
4 involve patients or the public in this work.

5 ***Search strategy***

6
7 A systematic computer-aided search of related studies will be conducted in the
8 following databases:
9

- 10
11 1. Ovid MEDLINE (1946 to June 30, 2019, including epub ahead of print, in process
12 and other non-indexed citations and daily)
- 13
14 2. Ovid Embase (1947 to June 2019)
- 15
16 3. Cochrane Database of Systematic Reviews (published on or before 30th June 2019)

17 ***Initial keywords***

18
19 The databases will be searched using the following initial keyword search terms:
20
21 coronary angiography; angiocardiograph; contrast medium; radiocontrast medium;
22
23 acute kidney injury; contrast-induced nephropathy; acute renal insufficiency; risk
24
25 factor; risk assessment; multivariate analysis; multivariable logistic regression; models.
26
27 We will restrict the search on the databases to English language publications. If we find
28
29 additional relevant keywords during any of the electronic searches, we will update the
30
31 electronic search strategies with these terms and document the changes (details in
32
33 Supplement).
34
35
36
37
38

39 ***Types of studies***

40
41 We will include all observational studies (registries, cohorts, etc.) that analyze the
42
43 correlation between risk factors and CI-AKI following procedures with contrast media.
44
45 This review will also consider experimental and epidemiological study designs,
46
47 including case-control and cohort studies, as being appropriate for inclusion in the
48
49 meta-analysis. However, we will exclude articles related to animal experiments.
50
51

52 ***Types of participants***

53
54 We will include adults identified with the CI-AKI who are aged 18 years and above.
55
56
57

58 ***Types of outcomes***

59 ***Primary outcome***

60

1
2
3
4 The primary endpoint will be CI-AKI, defined as an increase in serum creatinine after
5 exposure to contrast media.
6

7 ***Secondary outcome***

8
9 The secondary endpoint will be long-term all-cause mortality, defined as death from
10 any cause within the follow-up time of patient's post-index procedure.
11
12
13

14 15 **Selection of studies**

16
17 We will filter all retrieved articles. Two authors (XCL and SJX) will browse the titles
18 and abstracts independently, and will record the excluded documents and the reasons
19 for the exclusion. If there is a dispute in the process of the screening of the article, there
20 will be a third author (YL) to arbitrate. After the initial screening, the two authors (GLS
21 and JY) will then read the full text and further filter the articles according to the
22 inclusion and exclusion criteria mentioned above. To avoid overlapping patient data in
23 duplicate publications, registry analyses will be cross-checked with institutional studies
24 and compared with other registry studies, and the larger or more complete publication
25 will be included. In the process of reading the full text, if there is doubt in the selection,
26 the two authors (XCL and SJX) will discuss it. If it cannot be resolved, there will be a
27 third author (LY) to arbitrate. Finally, all selected articles will be listed for further
28 analysis, and the excluded articles will be classified according to the reasons for
29 exclusion.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Quality assessment/assessment of the risk of bias in included studies**

46 Two authors will independently assess the quality of selected articles using the
47 *Newcastle-Ottawa Scale*.⁸
48

49 ***Observational studies using Newcastle-Ottawa Scale:***

50 **CASE-CONTROL STUDIES**

51 **Selection**

- 52 1) Is the Case Definition Adequate?
- 53 2) Representativeness of the Cases
- 54 3) Selection of Controls
- 55 4) Definition of Controls

56 **Comparability**

57
58
59
60

1
2
3 1) Comparability of Cases and Controls on the Basis of the Design or Analysis

4 Exposure

5 1) Ascertainment of Exposure

6 2) Non-Response Rate

7 COHORT STUDIES

8 Selection

9 1) Representativeness of the Exposed Cohort

10 2) Selection of the Non-Exposed Cohort

11 3) Ascertainment of Exposure

12 4) Demonstration That Outcome of Interest Was Not Present at Start of Study

13 Comparability

14 1) Comparability of Cohorts on the Basis of the Design or Analysis

15 Outcome

16 1) Assessment of Outcome

17 2) Was Follow-Up Long Enough for Outcomes to Occur

18 3) Adequacy of Follow-Up of Cohorts

19 We will rate each selected article with a rating of low, high, or unclear, and the results
20 will be presented in the form of a table. In addition, we will use the Risk of Bias in
21 Nonrandomized studies of Interventions tool (ROBINS-I)⁹ to enhance the
22 reproducibility and comparability of this review to future reviews of a similar topic.
23
24
25
26
27
28
29
30
31
32

33 **Data synthesis:**

34 We will use STATA Ver13.0 software and RevMan for data analysis, and risk factor
35 effect sizes will be expressed as an odds ratio and their 95% CI. Using standard chi-
36 square test to assess the heterogeneity and variable statistics, we will perform subgroup
37 analysis to conduct data statistics. If there are data that cannot be counted in the selected
38 article, the data will be listed in the form of a table or chart. EndNote will be used for
39 managing references.
40
41
42
43
44
45
46

47 Sensitivity analysis. We will perform sensitivity analyses in order to explore the
48 influence of the following factors on effect sizes:
49

50 1. Restricting the analysis to studies of coronary angiography.

51 2. Restricting the analysis to large cohort studies with more than 1000 subjects.
52
53
54
55
56

57 **Meta-biases**

58 We will evaluate the possibility of publication bias using funnel plots and take Egger's
59
60

1
2
3
4 test of bias as a complement. Unpublished data will also be considered in the evaluation
5 of the publication bias, and we will try to contact the author for assistance in this regard.
6
7
8

9 **Confidence in cumulative evidence**

10 We will evaluate the strength of evidence for all outcomes by performing the Grading
11 of Recommendations Assessment, Development and Evaluation working group
12 methodology. The quality of evidence will be assessed across the domains of risk of
13 bias, precision, directness, consistency, and publication bias. Strength will be judged as
14 high (further research is improbable to alter our confidence in the estimate of effect),
15 moderate (further research will probably generate an important impact on our
16 confidence in the estimate of effect and may alter the estimate), low (further research
17 is very likely to generate an important impact on our confidence in the estimate of effect
18 and change the estimate), or very low (the estimate of effect is indeterminable).¹⁰
19
20
21
22
23
24
25
26
27
28
29
30

31 **Conclusion:**

32 The goal of this systematic review and meta-analysis is to clearly identify the important
33 risk factors for CI-AKI for the purpose of preferentially supplying target prevention
34 strategies, including contrast limiting and hydration for those high risk factors. In
35 addition, the modifiable, new, and controversial factors will also be evaluated, as they
36 may have potential as preventive targets.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Author affiliations**

52 *Contributions*

53 Yong Liu, Xingchen Liang, Shaojun Xin, Jin Liu, Guoli Sun, Shiqun Chen, Xiaolin
54 Cen, Xiaohua Dai, Yibo He, Feier Song, Yan Liang, Yuying Hu, Yingling Zhou,
55 Zhujun Chen, Ning Tan, Jiyan Chen: conception and design of the work; Yong Liu,
56 Xingchen Liang, Shaojun Xin, Xiaolin Cen, Xiaohua Dai: determining search terms,
57 related literature search; Yong Liu, Xingchen Liang, Shaojun Xin, Jin Liu, Guoli Sun,
58
59
60

1
2
3
4 Shiqun Chen, Xiaolin Cen, Xiaohua Dai, Yibo He, Feier Song: filter literature
5 according to established standards; Yan Liang, Yuying Hu, Yingling Zhou, Zhujun
6 Chen, Ning Tan, Jiyan Chen: as a third author, judge the doubtful literature; Yong Liu,
7 Shiqun Chen: acquisition, analysis, or interpretation of data; Yong Liu, Shiqun Chen,
8 Jiyan Chen, Yong Liu, Ning Tan: drafting the work or revising it critically for important
9 intellectual content. All authors agree that this is the final version of the article. All
10 authors agree to be accountable for all aspects of the work in ensuring that questions
11 related to the accuracy or integrity of any part of the work are appropriately investigated
12 and resolved.
13
14
15
16
17
18
19
20

21 ***Competing interests***

22
23 None declared
24

25 ***Funding***

26
27 The study is supported by the Science and Technology Planning Project of Guangdong
28 Province (grant no. 2014B070706010), The Technology Planning Project of Dongguan
29 Province (grant no. 2015108101022), The National Science Foundation for Young
30 Scientists of China (grant no. 81500520), and The Progress in Science and Technology
31 Project of Guangdong Province (grant no. 2015A030302037) .
32
33
34
35

36 ***Data sharing statement***

37
38 All authors will share all data.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc Interv* 2014;7(1):1-9. doi: 10.1016/j.jcin.2013.06.016
2. James MT, Samuel SM, Manning MA, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. *Circ Cardiovasc Interv* 2013;6(1):37-43. doi: 10.1161/CIRCINTERVENTIONS.112.974493
3. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. *N Engl J Med* 2019;380(22):2146-55. doi: 10.1056/NEJMra1805256
4. Gurm HS, Seth M, Kooiman J, et al. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 2013;61(22):2242-8. doi: 10.1016/j.jacc.2013.03.026
5. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004;44(7):1393-9. doi: 10.1016/j.jacc.2004.06.068
6. Allen DW, Ma B, Leung KC, et al. Risk Prediction Models for Contrast-Induced Acute Kidney Injury Accompanying Cardiac Catheterization: Systematic Review and Meta-analysis. *Can J Cardiol* 2017;33(6):724-36. doi: 10.1016/j.cjca.2017.01.018
7. Silver SA, Shah PM, Chertow GM, et al. Risk prediction models for contrast induced nephropathy: systematic review. *BMJ* 2015;351:h4395. doi: 10.1136/bmj.h4395
8. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [webpage on the Internet] Ottawa, ON: Ottawa Hospital Research Institute; 2011. [Accessed February 5, 2013]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

1
2
3
4 9. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of
5 bias in non-randomised studies of interventions. Bmj 2016;355:i4919. doi:

6
7 10.1136/bmj.i4919 [published Online First: 2016/10/14]

8
9 10. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
10 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
11 Bmj 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online First: 2015/01/04]
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Draft MEDLINE and EMBASE search - Ovid interface

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- 1. exp Contrast Media/
 - 2. (contrast media or contrast medium or contrast material\$ or contrast agent\$ or contrast dye or radiographic contrast).ti,ab.
 - 3. (radiocontrast media or radiocontrast medium or radiocontrast agent\$).ti,ab.
 - 4. 1 or 2 or 3
 - 5. (nephritis or nephropath\$ or nephrotoxic\$).ti,ab.
 - 6. ((impair\$ or damag\$ or reduc\$ or injur\$ dysfunction\$ or failure) adj2 (renal or kidney)).ti,ab.
 - 7. exp Kidney Diseases/
 - 8. exp nephritis/ or diabetic nephropathies/
 - 9. exp renal insufficiency/
 - 10. acute kidney injury.ti,ab.
 - 11. acute kidney injur*.ti,ab.
 - 12. acute kidney failure*.ti,ab.
 - 13. Acute kidney insufficienc*.ti,ab.
 - 14. contrast induced nephropathy
 - 15. contrast induced nephropath*.ti,ab.
 - 16. contrast nephropath*.ti,ab.
 - 17. contrast induced acute kidney injur*.ti,ab.
 - 18. AKI.ti,ab.
 - 19. ARF.ti,ab.
 - 20. CIN.ti,ab.
 - 21. acute renal injur*.ti,ab.
 - 22. acute renal failure*.ti,ab.
 - 23. acute renal insufficienc*.ti,ab.
 - 24. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
 - 25. Risk Assessment/
 - 26. risk factors/

- 1
- 2
- 3
- 4 -27. (risk adj3 model*).ti,ab.
- 5
- 6 -28. score*.ti,ab.
- 7
- 8 -29. Forecasting/
- 9
- 10 -30. prognostic factor*.ti,ab.
- 11
- 12 -31. "Predictive Value of Tests"/
- 13
- 14 -32. predict*.ti,ab.
- 15
- 16 -33. regression*.ti,ab.
- 17
- 18 -34. (logistic adj2 model*).ti,ab.
- 19
- 20 -35. multivariate analysis/
- 21
- 22 -36. multivariable logistic regression
- 23
- 24 -37. (multivariate adj3 analysis).ti,ab.
- 25
- 26 -38. sn.fs.
- 27
- 28 -39. exp mathematical concepts/
- 29
- 30 -40. exp Models, Biological/
- 31
- 32 -41. exp models, statistical/
- 33
- 34 -42. area under curve/
- 35
- 36 -43. algorithm*.ti,ab.
- 37
- 38 -44. equation*.ti,ab.
- 39
- 40 -45. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or
- 41 39 or 40 or 41 or 42 or 43 or 44
- 42
- 43 -46. 4 and 24 and 45
- 44
- 45 -47. remove duplicates from 46
- 46
- 47
- 48
- 49 Draft Cochrane database search
- 50
- 51 -1. (contrast media or contrast medium or contrast material\$ or contrast agent\$ or
- 52 contrast dye or radiographic contrast).ti,ab.
- 53
- 54 -2. (radiocontrast media or radiocontrast medium or radiocontrast agent\$).ti,ab.
- 55
- 56 -3. (percutaneous coronary intervention or PCI or coronary angiograph or
- 57 angiography or catheter-proven or Angioplasty).ti,ab.
- 58
- 59 -4. 1 or 2 or 3
- 60

1
2
3
4 -5. (nephritis or nephropath\$ or nephrotoxic\$).ti,ab.

5
6 -6. ((impair\$ or damag\$ or reduc\$ or injur\$ dysfunction\$ or failure) adj2 (renal or
7 kidney)).ti,ab.

8
9 -7. (Kidney Diseases or nephritis or diabetic nephropathies or renal insufficiency or
10 acute kidney injury or acute kidney injur* or acute kidney failure* or Acute kidney
11 insufficienc* or contrast induced nephropathy or contrast induced nephropath* or
12 contrast nephropath* or contrast induced acute kidney injur* or AKI or ARF or CIN
13 or acute renal injur* or acute renal failure* or acute renal insufficienc* or creatinine
14 or serum creatinine).ti,ab.

15
16
17
18
19
20
21 -8. 5 or 6 or 7

22
23 -9. ((risk adj3 model*) or score* or prognostic factor* or predict* or regression* or
24 (logistic adj2 model*) or multivariable logistic regression or multivariable analyses or
25 logistic regression or algorithm* or equation* or (multivariate adj3 analysis or
26 Forecasting or "Predictive Value of Tests" or multivariate analysis or mathematical
27 concepts or Models, Biological or models, statistical or area under curve)).ti,ab.

28
29
30
31
32
33 -10. 4 and 8 and 9
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a-P1	Identify the report as a protocol of a systematic review
Update	NO	If the protocol is for an update of a previous systematic review, identify as such
Registration	2-P2	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		
Contact	3a-P1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	3b-P1	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	NO	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a-P8	Indicate sources of financial or other support for the review
Sponsor	5b-P8	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c-P8	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	6-P3	Describe the rationale for the review in the context of what is already known
Objectives	7-P3	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		
Eligibility criteria	8-P6	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9-P4	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	10-P4	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:		
Data management	11a-P7	Describe the mechanism(s) that will be used to manage records and data throughout the review

Selection process	11b-P6	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	11c-P6	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
Data items	12-P6	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
Outcomes and prioritization	13-P5	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
Risk of bias in individual studies	14-P7	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	15a-P7	Describe criteria under which study data will be quantitatively synthesised
	15b-P7	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
	15c-P7	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
	15d-P7	If quantitative synthesis is not appropriate, describe the type of summary planned
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.